An update on primary hyperoxaluria.

Area of Science:

• Genetics
• Metabolic Disorders
• Nephrology

Background:

• Primary hyperoxalurias (PH) are inherited disorders of glyoxylate metabolism.
• These conditions lead to endogenous overproduction of oxalate, resulting in elevated urinary oxalate levels.
• The spectrum includes PH type I, II, and III, with type III identified in 2010.

Purpose of the Study:

• To summarize the current understanding of primary hyperoxalurias, including their genetic basis, clinical manifestations, and management.
• To highlight the importance of early diagnosis and intervention in preventing severe kidney damage and systemic oxalosis.
• To review current and potential treatment strategies, including medical management and transplantation.

Main Methods:

• Review of existing literature on primary hyperoxalurias.
• Analysis of clinical data regarding disease progression, diagnosis, and treatment outcomes.
• Comparison of management strategies across different PH types.

Main Results:

• Elevated urinary oxalate excretion (>1 mmol/1.73 m(2)/day) is a hallmark of all PH types.
• Complications include recurrent urolithiasis, nephrocalcinosis, kidney damage, and systemic oxalosis.
• End-stage renal disease (ESRD) affects over 30% of PH type I patients, often due to delayed diagnosis.
• Pyridoxine is effective in ~30% of PH type I patients; combined liver-kidney transplant is preferred for PH I, while isolated kidney transplant is used for PH II.
• No ESRD progression has been reported in PH type III patients to date.

Conclusions:

• Primary hyperoxalurias require timely diagnosis and management to prevent irreversible kidney damage and systemic oxalosis.
• Treatment strategies are type-specific and focus on reducing oxalate production, managing complications, and renal replacement therapy.
• Further research into novel therapeutic approaches is warranted.